Sydney - Wednesday - September 6: (RWE Aust Business News) - Life
Therapeutics (ASX:LFE) will supply Cangene Corp with anti-anthrax plasma
to produce a hyperimmune product for the US Department of Health and
Human Services.
This is a $US143m project for Cangene under Project BioShield to
produce 10,000 doses of anthrax immune globulin for treating inhalational
anthrax.